^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Cell Lung Cancer

    Related cancers:
    1d
    Thoracic Tumours Register (clinicaltrials.gov)
    P=N/A, N=10000, Recruiting, Spanish Lung Cancer Group | Trial completion date: Dec 2030 --> Dec 2031 | Trial primary completion date: Dec 2026 --> Dec 2030
    Trial completion date • Trial primary completion date
    1d
    YAP1 defines an emergent, plastic population of relapsed small cell lung cancer. (PubMed, J Thorac Oncol)
    As a result of this SCLC-like to LCNEC-like evolution, YAP1-positive cells lack several clinically relevant SCLC surface targets (i.e., DLL3, SEZ6), but are enriched for others (i.e., B7-H3, TROP2). We propose a model where YAP1 expressing cells emerge with SCLC treatment resistance and characterize a tenacious subpopulation capable of diverging from the treatment naïve lineage and adopting features to evade therapeutic response.
    Journal
    |
    CD276 (CD276 Molecule) • DLL3 (Delta Like Canonical Notch Ligand 3) • YAP1 (Yes associated protein 1) • SEZ6 (Seizure Related 6 Homolog)
    1d
    A Lay Navigation Intervention for Patients With Lung Cancer (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, University Health Network, Toronto
    New trial
    1d
    DURVALUNG: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, UNICANCER | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imfinzi (durvalumab)
    1d
    Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC (clinicaltrials.gov)
    P2, N=84, Not yet recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    |
    albumin-bound paclitaxel
    1d
    A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors (ChiCTR2600121742)
    P1, N=230, Recruiting, Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Institute); Sun Yat-sen University Cancer
    New P1 trial • First-in-human
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • capecitabine • Avzivi (bevacizumab-tnjn)
    1d
    A Clinical Study of Tislelizumab With or Without Anti‑Angiogenic Agents as Adjuvant Therapy After Neoadjuvant Treatment and Surgery in Patients With stage II–III Non‑Small Cell Lung Cancer (ChiCTR2600121659)
    P=N/A, N=60, Recruiting, General Hospital of Ningxia Medical University; General Hospital of Ningxia Medical University
    New trial
    |
    Tevimbra (tislelizumab-jsgr)
    1d
    Exhaled Breath Testing: A Non-Invasive Method for Predicting the Efficacy of Immunotherapy in Lung Cancer (ChiCTR2600121628)
    P=N/A, N=150, Peking University People's Hospital; Peking University People's Hospital
    New trial
    1d
    A randomized exploratory three-cohort study evaluating the impact of time-of-day administration on the efficacy and safety of serplulimab plus chemotherapy as neoadjuvant treatment for stage II– IIIb non-small-cell lung cancer (TD-LUNG-Timing) (ChiCTR2600121500)
    P2/3, N=120, Tangdu Hospital, Air Force Medical University; Tangdu Hospital, Air Force Medical University,
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Hetronifly (serplulimab)
    1d
    A real-world study of toripalimab in the treatment of advanced solid tumor patients in China (ChiCTR2600121488)
    P4, N=300, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New P4 trial • Real-world evidence
    |
    Loqtorzi (toripalimab-tpzi)
    1d
    Efficacy and Safety of Evolocumab as a Radiosensitizer in Locally Advanced Lung Cancer: A Single-Center, Open-Label, Randomized Controlled Trial (ChiCTR2600121237)
    P=N/A, N=82, Xi'an Jiaotong University Second Affiliated Hospital; Xi'an Jiaotong University Second Affiliated Hospital
    New trial
    |
    Repatha (evolocumab)
    1d
    Development and Validation of a Multimodal AI Model for Aided Diagnosis of High-risk Pulmonary Nodules Integrating cfDNA Methylation, Radiological, and Clinical Features (ChiCTR2600121194)
    P=N/A, N=1163, Peking University Shenzhen Hospital; Peking University Shenzhen Hospital
    New trial